Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States

Journal of Medical Economics

Volumn 15, Issue 5, 2012, Pages 997-1018

  Weiner, Leonard B ^a   Masaquel, Anthony S ^b   Polak, Mark J ^c   Mahadevia, Parthiv J ^a,b  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b MEDIMMUNE   (United States)

^c WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cost effectiveness; Medicaid; Palivizumab; Prophylaxis; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

ARTICLE; CHILD HOSPITALIZATION; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG APPROVAL; DRUG COST; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH INSURANCE; HIGH RISK INFANT; HOSPITAL ADMISSION; HUMAN; INFANT; MEDICAID; NEWBORN INTENSIVE CARE; PREMATURITY; QUALITY ADJUSTED LIFE YEAR; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RISK REDUCTION; UNITED STATES;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; GESTATIONAL AGE; HOSPITALIZATION; HUMANS; INFANT, NEWBORN; INSURANCE COVERAGE; INTENSIVE CARE UNITS; MEDICAID; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; UNITED STATES;

EID: 84865266609     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.672942     Document Type: Article

References (90)

1. Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr 2003;143; S127-32
2. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143; 532-40
3. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102; 531-7
4. Bockova J, O'Brien KL, Oski J, et al. Respiratory syncytial virus infection in Navajo and White Mountain Apache children. Pediatrics 2002;110; e20
5. Bulkow LR, Singleton RJ, Karron RA, et al. Risk factors for severe respiratory syncytial virus infection among Alaska native children. Pediatrics 2002;109; 210-6
6. Holman RC, Curns AT, Cheek JE, et al. Respiratory syncytial virus hospitalizations among American Indian and Alaska Native infants and the general United States infant population. Pediatrics 2004;114; e437-44
7. Karron RA, Singleton RJ, Bulkow L, et al. Severe respiratory syncytial virus disease in Alaska native children. RSV Alaska Study Group. J Infect Dis 1999;180; 41-9
8. La Via WV, Grant SW, Stutman HR, et al. Clinical profile of pediatric patients hospitalized with respiratory syncytial virus infection. Clin Pediatr (Phila) 1993;32; 450-4
9. Sangaré L, Curtis MP, Ahmad S. Hospitalization for respiratory syncytial virus among California infants: Disparities related to race, insurance, and geography. J Pediatr 2006;149; 373-7
10. Singleton RJ, Petersen KM, Berner JE, et al. Hospitalizations for respiratory syncytial virus infection in Alaska Native children. Pediatr Infect Dis J 1995;14; 26-30
11. Wadhwa PD, Culhane JF, Rauh V, et al. Stress, infection and preterm birth: A biobehavioural perspective. Paediatr Perinat Epidemiol 2001;15 Suppl 2, 17-29
12. Kramer MS, Goulet L, Lydon J, et al. Socio-economic disparities in preterm birth: Causal pathways and mechanisms. Paediatr Perinat Epidemiol 2001;15 Suppl 2, 104-23
13. Moutquin JM. Socio-economic and psychosocial factors in the management and prevention of preterm labour. BJOG 2003;110 Suppl 20, 56-60
14. StateHealthFacts.org. Medicaid coverage rates for the nonelderly by race/ethnicity, states (2009-2010), U.S. (2010) Available at: Http://www.statehealthfacts. org/comparetable.jsp?ind163&cat3&sub42 Accessed January 23, 2012.
15. Boyce TG, Mellen BG, Mitchel Jr EF, et al. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr 2000;137; 865-70
16. Frogel M, Nerwen C, Cohen A, et al. Prevention of hospitalization due to respiratory syncytial virus: Results from the Palivizumab Outcomes Registry. J Perinatol 2008;28; 511-7
17. Synagis- (palivizumab). Full Prescribing Information, MedImmune, LLC., Gaithersburg, MD, 2011
18. American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, Baker CJ, Kimberlin DW, Red Book: 2009 Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics, 2009 560-69
19. American Academy of Pediatrics. Fact sheet. Medicaid and children. Available at: Http://www2.aap.org/research/factsheet.pdf Accessed February 6, 2012.
20. Data on File. MedImmune, LLC., Gaithersburg, MD 21. Hampp C, Kauf TL, Saidi AS, et al. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications. Arch Pediatr Adolesc Med 2011;165; 498-505
21. Shireman TI, Braman KS. Impact and cost-effectiveness of respiratory syncytial virus prophylaxis for Kansas medicaid's high-risk children. Arch Pediatr Adolesc Med 2002;156; 1251-5
22. Wegner S, Vann JJ, Liu G, et al. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: Evidence from the North Carolina Medicaid Program. Pediatrics 2004;114; 1612-9
23. Shi N, Palmer L, Chu B-C, et al. Association of RSV lower respiratory tract infection and subsequent healthcare use and costs: A Medicaid claims analysis in early-preterm, late-preterm, and full-term infants. J Med Econ 2011;14; 335-40
24. Levinson DR. Medicaid Brand-Name Drugs: Rising Prices Are Offset By Manufacturer Rebates. Office of Inspector General. Available at: Http://oig.hhs.gov/oei/reports/oei-03-10-00260.pdf Accessed January 17, 2012.
25. Mullins CD, Seal B, Seoane-Vazquez E, et al. Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: The ISPOR Drug Cost Task Force report-Part IV. Value Health 2010;13; 18-24
26. Government Printing Office. United States Code, Title 42 - The Public Health and Welfare; Section 1396r-8-payment for covered outpatient drugs. Available at: Http://www.gpo.gov/fdsys/pkg/USCODE-2010-title42/html/USCODE-2010- title42-chap7-subchapXIX-sec1396r-8.htm. Accessed March 12, 2012.
27. Stratton KR, Durch JS, Lawrence RS, et al, eds. Vaccines for the 21st Century: A Tool for Decisionmaking: The National Academies Press, 2000
28. Gold MR, Siegal JE, Russell LB, et al. Cost-effectiveness in health and medicine. Oxford University Press, 1996
29. Figueras-Aloy J, Carbonell-Estrany X, Quero J. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J 2004;23; 815-20
30. Law BJ, Langley JM, Allen U, et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 2004;23; 806-14
31. Figueras-Aloy J, Carbonell-Estrany X, Quero-Jimenez J, et al. FLIP-2 Study: Risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J 2008;27; 788-93
32. Stensballe LG, Fullarton JR, Carbonell-Estrany X, et al. Population based external validation of a European predictive model for respiratory syncytial virus hospitalization of premature infants born 33 to 35 weeks of gestational age. Pediatr Infect Dis J 2010;29; 374-6
33. Rietveld E, Vergouwe Y, Steyerberg EW, et al. Hospitalization for respiratory syncytial virus infection in young children: Development of a clinical prediction rule. Pediatr Infect Dis J 2006;25; 201-7
34. Lanctot KL, Masoud ST, Paes BA, et al. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: A Canadian-based analysis. Curr Med Res Opin 2008;24; 3223-37
35. Simoes EA. RSV disease in the pediatric population: Epidemiology, seasonal variability, and long-term outcomes. Manag Care 2008;17; 3-6, discussion 18-9
36. Sampalis JS, Langley J, Carbonell-Estrany X, et al. Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Making 2008;28; 471-80
37. Paes B, Cole M, Latchman A, et al. Predictive value of the respiratory syncytial virus risk-scoring tool in the term infant in Canada. Curr Med Res Opin 2009;25; 2191-6
38. Paes B, Steele S, Janes M, et al. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada. Curr Med Res Opin 2009;25; 1585-91
39. Tam DY, Banerji A, Paes BA, et al. The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic. J Med Econ 2009;12; 361-70
40. Roeckl-Wiedmann I, Liese JG, Grill E, et al. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. Eur J Pediatr 2003;162; 237-44
41. Farina D, Rodriguez SP, Bauer G, et al. Respiratory syncytial virus prophylaxis: Cost-effective analysis in Argentina. Pediatr Infect Dis J 2002;21; 287-91
42. Simpson S, Burls A. A systematic review of the effectiveness and cost-effectiveness of palivizumab (Synagis) in the prevention of respiratory syncytial virus (RSV) infection in infants at high risk of infection. Department of Public Health & Epidemiology, University of Birmingham. Available at: Http://www.rep.bham.ac.uk/2001/Palivizumab-final-post-panel.pdf Accessed January 17, 2012.
43. Detsky AS, Laupacis A. Relevance of cost-effectiveness analysis to clinicians and policy makers. JAMA 2007;298; 221-4
44. Palmer L, Hall CB, Katkin JP, et al. Healthcare costs within a year of respiratory syncytial virus among Medicaid infants. Pediatr Pulmonol 2010;45; 772-81
45. Centers for Disease Control and Prevention. US Vital Statistics. Available at: Http://www.cdc.gov/nchs/nvss.htm Accessed January 17, 2012.
46. Wills S, Simpson JH, Coutts J. Cost minimisation of RSV prevention with palivizumab. Arch Dis Child 2006;91; 717
47. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008;359; 821-32
48. Prosser LA, Bridges CB, Uyeki TM, et al. Health benefits, risks, and costeffectiveness of influenza vaccination of children. Emerg Infect Dis 2006;12; 1548-58
49. Chesson H. HPV Vaccine Cost-effectiveness Updates and Review. Available at: Http://www.cdc.gov/vaccines/recs/acip/downloads/mtg-slides-jun11/07-5-hpv- cost-effect.pdf Accessed January 17, 2012.
50. National Network for Immunization Information. Vaccine Economics. Available at: Http://www.immunizationinfo.org/issues/immunization-policy/ vaccineeconomics.
51. Accessed March 12, 2012.
52. Moore L, Remy V, Martin M, et al. A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. Cost Eff Resour Alloc 2010;8; 7
53. Blais LR, Williams LB, Lamoureux VA. A novel home-care based program for palivizumab prophylaxis reduces RSV hospitalization. Pediatr Res 2004;55; 589A
54. Goldenring J. Give Synagis via home health. Pediatrics 2007;119; 219
55. Checchia PA, Nalysnyk L, Fernandes AW, et al. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: A systematic literature review and meta-Analysis. Pediatr Crit Care Med 2011;12; 580-8
56. Finkelstein JA, Barton MB, Donahue JG, et al. Comparing asthma care for Medicaid and non-Medicaid children in a health maintenance organization. Arch Pediatr Adolesc Med 2000;154; 563-8
57. Peterson TH, Peterson T, Armon C, et al. Insurance-Associated disparities in hospitalization outcomes of Michigan children. J Pediatr 2011;158; 313-8 e1-2
58. Forbes ML, Hall CB, Jackson A, et al. Comparative costs of hospitalisation among infants at high risk for respiratory syncytial virus lower respiratory tract infection during the first year of life. J Med Econ 2010;13; 136-41
59. Horn SD, Smout RJ. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr 2003;143; S133-41
60. Gunville CF, Sontag MK, Stratton KA, et al. Scope and impact of early and late preterm infants admitted to the PICU with respiratory illness. J Pediatr 2010;157; 209-14 e1
61. Thorburn K. Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection. Arch Dis Child 2009;94; 99-103
62. US Department of Labor. Bureau of Labor Statistics for 2010 (May to Aug) Available at: Http://www.dol.gov/ Accessed April 20, 2011.
63. Guo SS. Growth in weight, recumbent length, and head circumference for preterm low-birth weight infants during the first three years of life using gestation-Adjusted ages. Early Hum Dev 1997;47; 305-25
64. Centers for Disease Control and Prevention. Natality public use file. Available at: Http://www.cdc.gov/nchs/births.htm Accessed April 20, 2011.
65. Luce BR, Zangwill KM, Palmer CS, et al. Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children. Pediatrics 2001;108; E24
66. Leidy NK, Margolis MK, Marcin JP, et al. The impact of severe respiratory syncytial virus on the child, caregiver, and family during hospitalization and recovery. Pediatrics 2005;115; 1536-46
67. Azimi NA, Welch HG. The effectiveness of cost-effectiveness analysis in containing costs. J Gen Intern Med 1998;13; 664-9
68. Elhassan NO, Sorbero ME, Hall CB, et al. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med 2006;160; 1070-6
69. Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003;163; 1637-41
70. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003;290; 781-9
71. Purdy KW, Hay JW, Botteman MF, et al. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: A cost-benefit analysis. Clin Infect Dis 2004;39; 20-8
72. Shim E, Galvani AP. Impact of transmission dynamics on the costeffectiveness of rotavirus vaccination. Vaccine 2009;27; 4025-30
73. Ortega-Sanchez IR. Cost-Effectiveness of Meningococcal Vaccination in Infants and Toddlers in the United States. Available at: Http://www.cdc.gov/ vaccines/recs/acip/downloads/mtg-slides-oct11/03-MCV-Ortega-Sanchez. pdf Accessed January 12, 2012.
74. Jacobs RJ, Saab S, Meyerhoff AS. The cost effectiveness of hepatitis immunization for US college students. J Am Coll Health 2003;51; 227-36
75. Yount LE, Mahle WT. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics 2004;114; 1606-11
76. Sampalis JS. Morbidity and mortality after RSV-Associated hospitalizations among premature Canadian infants. J Pediatr 2003;143; S150-6
77. Thomson Healthcare, Inc. Red Book Drug Topics. Montvale, NJ: PDR Network, LLC, 2010
78. Briggs AH, Claxton K, Sculpher MJ. Decision modelling for health economic evaluation. Oxford: Oxford University Press, 2006
79. Smart KA, Lanctot KL, Paes BA. The cost effectiveness of palivizumab: A systematic review of the evidence. J Med Econ 2010;13; 453-63
80. Flaherman V, Li S, Ragins A, et al. Respiratory syncytial virus testing during bronchiolitis episodes of care in an integrated health care delivery system: A retrospective cohort study. Clin Ther 2010;32; 2220-9
81. Mays VM, Cochran SD, Barnes NW. Race, race-based discrimination, and health outcomes among African Americans. Annu Rev Psychol 2007;58; 201-25
82. Tobacco use among U.S. racial/ethnic minority groups-African Americans, American Indians and Alaska Natives, Asian Americans and Pacific Islanders, Hispanics. A Report of the Surgeon General. Executive summary. MMWR Recomm Rep 1998;47; v-xv, 1-16
83. Frogel MP, Stewart DL, Hoopes M, et al. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis. J Manag Care Pharm 2010;16; 46-58
84. Ray GT, Whitney CG, Fireman BH, et al. Cost-effectiveness of pneumococcal conjugate vaccine: Evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J 2006;25; 494-501
85. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004;96; 604-15
86. Shepard CW, Ortega-Sanchez IR, Scott 2nd RD, et al. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics 2005;115; 1220-32
87. Gooch K, Busch K, Khong H. Length of Hospital Stay for Respiratory Syncytial Virus in Prophylaxed Versus Non-Prophylaxed Premature Infants. Presented at: European Society for Paediatric Infectious Diseases; June 7-11, 2011; The Hague, The Netherlands 88. Paramore LC, Ciuryla V, Ciesla G, et al. Economic impact of respiratory syncytial virus-related illness in the US: An analysis of national databases. Pharmacoeconomics 2004;22; 275-84
88. Paramore LC, Mahadevia PJ, Piedra PA. Outpatient RSV lower respiratory infections among high-risk infants and other pediatric populations. Pediatr Pulmonol 2010;45; 578-84
89. Mittmann N, Trakas K, Risebrough N, et al. Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics 1999;15; 369-76
90. Simoes EA, Groothuis JR, Carbonell-Estrany X, et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr 2007;151; 34-42, 42.e.1